Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLC
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Jaime Rubio-Perez, Elena Garralda, Benjamin Besse, Mihaela Aldea, Yasir Elamin, Pilar Garrido, Saad Khan, Judy Wang, Luis Paz Ares, Daniel Morgensztern, Philippe Cassier, Salmon Punekar, Stephen V Liu, Matthew H Taylor, Liz Joseph, Andrew G Gianoukakis, Jacobi Hines, Javier Garcia-Corbacho, Pascale Tomasini, David Spigel, Matthew G Krebs, Antoine Italiano, Mohammad Al Masri, Geoff Fisher, Sonia Serrano, Hendrik-Tobias Arkenau, Alex Drilon
Institutions: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Hospital Universitario Ramón y Cajal, Stanford University, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Washington University in St. Louis, Centre Léon Bérard, NYU Langone Health, New York University, Georgetown University, Georgetown University Medical Center, Providence Portland Medical Center, University College London Hospitals NHS Foundation Trust, University of California, Los Angeles, The Lundquist Institute, Harbor–UCLA Medical Center, Northwestern University, Instituto de Investigación Biomédica de Málaga, Assistance Publique Hôpitaux de Marseille, Sarah Cannon, University of Manchester, The Christie NHS Foundation Trust, Institut Bergonié, Cleveland Clinic Abu Dhabi
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154726008
Cites:
Cited by:
Related to: